Biologically Active Small Molecules

A potent, reversible, and cell permeable proteasome inhibitor a more effective inhibitor of chymotrypsin-like, trypsin-like, and peptidylglutamyl peptide hydrolyzing proteasome activities compared to (S)-MG132 (IC₅₀s = 0.22 versus 0.

A potent, reversible, and cell permeable proteasome inhibitor a more effective inhibitor of chymotrypsin-like, trypsin-like, and peptidylglutamyl peptide hydrolyzing proteasome activities compared to (S)-MG132 (IC₅₀s = 0.22 versus 0.

A nitro group-containing blebbistatin analog with the same stereochemistry as the inactive enantiomer, (+)-blebbistatin.

A nitro group-containing blebbistatin analog with the same stereochemistry as the inactive enantiomer, (+)-blebbistatin.

A nitro group-containing blebbistatin analog with the same stereochemistry as the inactive enantiomer, (+)-blebbistatin.

The inactive isomer of omeprazole, a gastric proton-pump inhibitor its hydroxylation is mediated stereoselectively by CYP2C19.

The inactive isomer of omeprazole, a gastric proton-pump inhibitor its hydroxylation is mediated stereoselectively by CYP2C19.

The inactive isomer of omeprazole, a gastric proton-pump inhibitor its hydroxylation is mediated stereoselectively by CYP2C19.

A potent, cell-permeable inhibitor of SET7/9 (IC₅₀ = 2 nM) that demonstrates greater than 1,000-fold selectivity over a panel of 18 other methyltransferases.

A potent, cell-permeable inhibitor of SET7/9 (IC₅₀ = 2 nM) that demonstrates greater than 1,000-fold selectivity over a panel of 18 other methyltransferases.

A potent, cell-permeable inhibitor of SET7/9 (IC₅₀ = 2 nM) that demonstrates greater than 1,000-fold selectivity over a panel of 18 other methyltransferases.

A potent, cell-permeable inhibitor of SET7/9 (IC₅₀ = 2 nM) that demonstrates greater than 1,000-fold selectivity over a panel of 18 other methyltransferases.